Antigen Presentation

• 

  Subject Areas on Research

  • A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. 
  • A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. 
  • A single amino acid defines cross-species reactivity of tree shrew (Tupaia belangeri) CD1d to human invariant natural killer T (iNKT) cells. 
  • A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. 
  • A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Adjuvant-free in vivo targeting. Antigen delivery by alpha 2-macroglobulin enhances antibody formation. 
  • Agent-based modeling of the context dependency in T cell recognition. 
  • Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. 
  • Alpha 2-macroglobulin: a sensor for proteolysis. 
  • Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. 
  • B cell antigen receptor endocytosis and antigen presentation to T cells require Vav and dynamin. 
  • B-lymphocyte contributions to human autoimmune disease. 
  • CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. 
  • CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. 
  • CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. 
  • Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. 
  • Cancer genes disfavoring T cell immunity identified via integrated systems approach. 
  • Cell-based vaccines for the stimulation of immunity to metastatic cancers. 
  • Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling. 
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. 
  • Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. 
  • Conditional Silencing of H-2Db Class I Molecule Expression Modulates the Protective and Pathogenic Kinetics of Virus-Antigen-Specific CD8 T Cell Responses during Theiler's Virus Infection. 
  • Construction and destruction of MHC class I in the peptide-loading complex. 
  • Costimulation, coinhibition and cancer. 
  • Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. 
  • Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. 
  • Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses. 
  • DNA vaccines and immunity to herpes simplex virus. 
  • Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. 
  • Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. 
  • Disease-Specific Expression of Conjunctiva Associated Lymphoid Tissue (CALT) in Mouse Models of Dry Eye Disease and Ocular Allergy. 
  • Down-regulation of MHC class I antigen presentation by HCMV; lessons for tumor immunology. 
  • ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. 
  • Effective effectors: How T cells access and infiltrate the central nervous system. 
  • Efficient dendritic cell priming of T lymphocytes depends on the extracellular matrix protein mindin. 
  • Emerging roles for lipid droplets in immunity and host-pathogen interactions. 
  • Endothelial antigen presentation: stimulation of previously activated but not naïve TCR-transgenic mouse T cells. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. 
  • Graft-versus-host disease: the viewpoint from the donor T cell. 
  • HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. 
  • HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses. 
  • Harnessing virus tropism for dendritic cells for vaccine design. 
  • Heat shock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivity. 
  • Herpes simplex virus blocks intracellular transport of HLA-G in placentally derived human cells. 
  • High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes. 
  • Host priming, not target antigen type, decides rejection rate in mice primed with MHC II "knockout" cultured keratinocytes. 
  • ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. 
  • Identification of self-lipids presented by CD1c and CD1d proteins. 
  • Ig VH hypermutation is absent in the germinal centers of aged mice. 
  • Immune interactions at the maternal-fetal interface: a focus on antigen presentation. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunologic targeting of FOXP3 in inflammatory breast cancer cells. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapy of cancer using dendritic cells. 
  • Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. 
  • In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. 
  • In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. 
  • Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. 
  • Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. 
  • Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. 
  • Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. 
  • Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxin. 
  • Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. 
  • Introduction: Regulatory B Cell Special Issue-making all the pieces fit. 
  • Involvement of an ATP-dependent peptide chaperone in cross-presentation after DNA immunization. 
  • Isolation and generation of human dendritic cells. 
  • Linking immune responses with fibrosis in allergic eye disease. 
  • Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. 
  • Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • Macrophage activation downregulates the degradative capacity of the phagosome. 
  • Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. 
  • Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 
  • Mast cell activators as novel immune regulators. 
  • Mast cell modulation of immune responses to bacteria. 
  • Mechanisms of inflammation and leukocyte activation. 
  • Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. 
  • Microglia and Perivascular Macrophages Act as Antigen Presenting Cells to Promote CD8 T Cell Infiltration of the Brain. 
  • Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. 
  • Mutant p53 as an Antigen in Cancer Immunotherapy. 
  • NLRC3 expression in dendritic cells attenuates CD4+ T cell response and autoimmunity. 
  • Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses. 
  • Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. 
  • Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. 
  • Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. 
  • Optimizing dendritic cell function by genetic modification. 
  • Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. 
  • Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Premature translational termination products are rapidly degraded substrates for MHC class I presentation. 
  • Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. 
  • Qa-2-dependent selection of CD8alpha/alpha T cell receptor alpha/beta(+) cells in murine intestinal intraepithelial lymphocytes. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages. 
  • Redundancy renders the glycoprotein 96 receptor scavenger receptor A dispensable for cross priming in vivo. 
  • Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. 
  • Regulatory B10 cell development and function. 
  • Rhoptry and Dense Granule Secreted Effectors Regulate CD8+ T Cell Recognition of Toxoplasma gondii Infected Host Cells. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Role of chaperones in antigen processing. 
  • Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. 
  • Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. 
  • Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. 
  • Status of activation of circulating vaccine-elicited CD8+ T cells. 
  • Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope. 
  • T cell engagement of cross-presenting microglia protects the brain from a nasal virus infection. 
  • T cells as a self-referential, sensory organ. 
  • T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. 
  • Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. 
  • The DRiP hypothesis decennial: support, controversy, refinement and extension. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. 
  • The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif. 
  • The effector component of the cytotoxic T-lymphocyte response has a biphasic pattern after burn injury. 
  • The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? 
  • Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. 
  • Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. 
  • Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. 
  • Vav and Rac activation in B cell antigen receptor endocytosis involves Vav recruitment to the adapter protein LAB. 
  • Viral subversion of the immune system. 
  • Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. 
• 

  Keywords of People

  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zhong, Xiaoping, Professor of Pediatrics, Integrative Immunobiology